GlassScriptPhysician profile
Corinne Ansbro
NPI 1497487482
$2,023.95
in general payments reported to CMS, 2019-2025
24 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $548 · 2023: $839 · 2024: $400 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.19 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $344.47 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $189.67 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.48 | 2022-2024 | Farxiga, Lynparza |
| Otsuka America Pharmaceutical, INC. | $166.42 | 2022-2023 | Rexulti |
| Array Biopharma INC | $141.67 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Lilly USA, LLC | $132.13 | 2022-2023 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.29 | 2022 | |
| Abbvie INC. | $77.57 | 2024-2025 | |
| Kite Pharma, INC. | $76.01 | 2024-2025 | Yescarta |
| Dexcom, INC. | $67.53 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $63.77 | 2022-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.05 | 2022-2023 | Synjardy, Jardiance, Trijardy Xr |
| Celgene Corporation | $60.50 | 2024 | Opdualag |
| Sobi, INC | $50.36 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.40 | 2022 | |
| Amgen INC. | $37.64 | 2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $30.10 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $24.78 | 2023 | |
| Exact Sciences Corporation | $22.12 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.48 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $18.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.60 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $14.13 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinne Ansbro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.